Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC

被引：9
|
作者：
Piotrowska, Zofia
Liu, Stephen V.
Muzikansky, Alona
Marcoux, Nicolas
Banwait, Mandeep
Stevens, Sara
Goodwin, Kelly
Lafferty, Tracey E.
Ackil, Jennifer
Krueger, Elizabeth A.
Heist, Rebecca Suk
Lin, Jessica Jiyeong
Gainor, Justin F.
Hata, Aaron N.
Shaw, Alice Tsang
Sequist, Lecia V.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21231
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [32] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
    Morise, Masahiro
    Sakai, Hiroshi
    Kato, Terufumi
    Tokito, Takaaki
    Takeda, Masayuki
    Tanaka, Hiroshi
    Chikamori, Kenichi
    Daga, Haruko
    Kijima, Takashi
    Ohashi, Kadoaki
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
  • [33] Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib plus /- Radiation Therapy in a Real-World Canadian Cohort
    Litt, I.
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Bebb, G.
    Cheung, W.
    Pabani, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S434 - S434
  • [34] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
    Nguyen, D.
    Besse, B.
    Cho, B. C.
    Lee, S. -H.
    Lee, K. H.
    Lu, S.
    Cheng, Y.
    Yao, Y.
    Girard, N.
    Lin, C. -C.
    Felip, E.
    Aguilar, A.
    Charoentum, C.
    Cruz, F. J. S. M.
    Majem, M.
    Lim, C. S.
    Akamatsu, H.
    Hayashi, H.
    Yang, J. C. -H.
    Kowalyszyn, R.
    Tiscoski, K.
    Franke, F.
    Ponomarenko, D.
    Arslan, C.
    Forster, M.
    Urban, D.
    Misch, D.
    Delmonte, A.
    Montes, L. V. G.
    Gadgeel, S. M.
    Cruz-Correa, M.
    Peguero, J.
    Rousey, S.
    Gaffar, Y.
    Owen, S.
    Schuchard, J.
    Diels, J.
    Sermon, J.
    Sun, T.
    Ennis, M.
    Fennema, E.
    Daksh, M.
    Sethi, S.
    Bauml, J. M.
    Garcia Campelo, M. R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
  • [35] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [36] Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo Vailati
    Nilsson, Monique B.
    Robichaux, Jacqulyne Ponville
    Boyle, Theresa A.
    Hicks, James Kevin
    Roarty, Emily
    Rinsurongkawong, Waree
    Glisson, Bonnie S.
    Zhangx, Jianjun
    Papadimitrakopoulou, Vassiliki
    Gray, Jhanelle Elaine
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Sun, Hao
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : E12 - E14
  • [38] Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting
    Uprety, Dipesh
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 371 - 374
  • [39] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
    Wei, Fang
    An, Juan
    Hua, Yichun
    Ding, Xiaosheng
    Sun, Shibin
    Li, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Laurila, Niina
    Koivunen, Jussi P.
    MEDICAL ONCOLOGY, 2015, 32 (07)
12345